Reacción a "Reactions to the approval of lecanemab for the treatment of Alzheimer's patients in the US"

This is clearly great news and heralds a sea change in our views about Alzheimer’s disease: there are now drugs which all agree slow the underlying disease process.  This, from Eisai, is the first, and it is likely that the equivalent drug from Lilly is close behind.  Safe administration of these drugs to the appropriate patient group will pose an organisational challenge to the NHS, but this is wonderful news.  It is worth noting that the UK Alzheimer charities funded the original work leading to this breakthrough and are now funding initiatives to help prepare for appropriate patient identification.